{"id":"amoxicillin-clarithromycin","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Diarrhea"},{"rate":"5-15","effect":"Nausea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"3-8","effect":"Vomiting"},{"rate":"1-3","effect":"Rash"},{"rate":"1-2","effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":{"setId":"0cb2ee04-8581-46c8-a781-7be170ab5c86","title":"VOQUEZNA DUAL PAK (VONOPRAZAN FUMARATE AND AMOXICILLIN) KIT VOQUEZNA TRIPLE PAK (VONOPRAZAN FUMARATE, AMOXICILLIN AND CLARITHROMYCIN) KIT [PHATHOM PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Together, they provide synergistic antimicrobial activity and are frequently used as part of triple or quadruple therapy regimens for Helicobacter pylori infection.","oneSentence":"Amoxicillin and clarithromycin are antibiotics that work together to inhibit bacterial protein synthesis and cell wall formation, commonly used in combination therapy for H. pylori eradication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:46.970Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori infection (as part of combination therapy)"},{"name":"Respiratory tract infections"},{"name":"Gastrointestinal infections"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT07455448","phase":"","title":"Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-03","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":7228},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07408271","phase":"","title":"The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-24","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication Antibiotic","enrollment":83},{"nctId":"NCT07293910","phase":"PHASE2","title":"Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-15","conditions":"HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":66},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT07382661","phase":"PHASE1","title":"Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin","status":"NOT_YET_RECRUITING","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Healthy Adult Volunteers","enrollment":36},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":"Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth","enrollment":56},{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":"Dyspepsia","enrollment":66},{"nctId":"NCT06510010","phase":"PHASE2","title":"Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2024-12-31","conditions":"Chemotherapy Effect","enrollment":198},{"nctId":"NCT05647278","phase":"PHASE4","title":"Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)","status":"COMPLETED","sponsor":"Zhang Xiaofeng,MD","startDate":"2023-11-01","conditions":"Helicobacter Pylori Infection","enrollment":370},{"nctId":"NCT06349486","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2023-11-28","conditions":"Helicobacter Pylori Eradication","enrollment":390},{"nctId":"NCT07294846","phase":"PHASE1","title":"Drug Interaction Study on Linaprazan Glurate Capsules","status":"COMPLETED","sponsor":"Jiangsu Sinorda Biomedicine Co., Ltd","startDate":"2025-09-08","conditions":"Healthy Volunteers, Patients","enrollment":56},{"nctId":"NCT07312721","phase":"PHASE4","title":"Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis","status":"COMPLETED","sponsor":"Azfar Farogh","startDate":"2024-01-05","conditions":"Helicobacter Pylori Infection, Chronic Gastritis, Peptic Ulcer Disease","enrollment":752},{"nctId":"NCT07275827","phase":"PHASE3","title":"Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":88},{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT05926804","phase":"NA","title":"A \"Screen and Treat\" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile","status":"RECRUITING","sponsor":"Miguel O'Ryan Gallardo","startDate":"2022-08-02","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects","enrollment":461},{"nctId":"NCT07246681","phase":"PHASE3","title":"Lignin in Treatment of Helicobacter Pylori Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zagazig University","startDate":"2025-10-31","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":70},{"nctId":"NCT07211880","phase":"NA","title":"Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study","status":"COMPLETED","sponsor":"Zero Helicobacter IGAN Network","startDate":"2019-12-05","conditions":"H.Pylori, Gastric Cancer, H Pylori Eradication","enrollment":1043},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT03431688","phase":"NA","title":"Tailored Therapy for Clarithromycin-Resistant H. Pylori","status":"COMPLETED","sponsor":"Kangdong Sacred Heart Hospital","startDate":"2018-10-01","conditions":"Helicobacter Pylori Infection","enrollment":782},{"nctId":"NCT07148622","phase":"NA","title":"Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2024-10-01","conditions":"Preterm Premature Rupture of Membranes (PPROM), Prophylaxis, Perinatal Outcomes","enrollment":40},{"nctId":"NCT07146594","phase":"PHASE4","title":"Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Athens Medical Center","startDate":"2025-08-20","conditions":"Helicobacter Pylori Gastritis, Helicobacter Eradication","enrollment":150},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT07122024","phase":"PHASE4","title":"Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-02-19","conditions":"Helicobacter Pylori","enrollment":414},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT07115173","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-12-01","conditions":"Helicobacter Infection","enrollment":103},{"nctId":"NCT06804096","phase":"PHASE4","title":"Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)","status":"RECRUITING","sponsor":"Dr. Md. Alimur Reza","startDate":"2025-02-20","conditions":"Pneumonia, Community-Acquired, Bacterial Pneumonia","enrollment":160},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":558},{"nctId":"NCT06523764","phase":"PHASE4","title":"Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-11-11","conditions":"Helicobacter Pylori Infection Chronic Gastrit","enrollment":208},{"nctId":"NCT05742568","phase":"PHASE4","title":"Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-12-01","conditions":"Gastritis, Dyspepsia, Helicobacter Pylori Infection","enrollment":124},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT07021729","phase":"PHASE4","title":"Comparison of Two Treatment Regimens of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-12","conditions":"Helicobacter Pylori Infection","enrollment":156},{"nctId":"NCT06959368","phase":"PHASE4","title":"Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication","status":"RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2025-03-25","conditions":"Helicobacter Pylori Infection","enrollment":484},{"nctId":"NCT06973889","phase":"PHASE2","title":"Evaluation of IgY Antibody Efficacy in Egg Yolk Against Helicobacter Pylori in Bacterial Elimination and Clinical Symptoms Improvement of Gastrointestinal Patients","status":"COMPLETED","sponsor":"Mashhad University of Medical Sciences","startDate":"2023-12-04","conditions":"HELICOBACTER PYLORI INFECTIONS, Gastrointestinal Disease","enrollment":60},{"nctId":"NCT06964334","phase":"PHASE3","title":"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-06-01","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT02047994","phase":"PHASE4","title":"Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality","status":"RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2013-03","conditions":"Helicobacter Pylori Infections, Atrophic Gastritis, Gastric Cancer","enrollment":30000},{"nctId":"NCT03130452","phase":"PHASE4","title":"Helicobacter Pylori Eradication Study","status":"COMPLETED","sponsor":"Inje University","startDate":"2016-12-17","conditions":"Helicobacter Pylori Infection","enrollment":423},{"nctId":"NCT06431737","phase":"","title":"Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2024-04-01","conditions":"H.Pylori Infection","enrollment":100},{"nctId":"NCT06682533","phase":"","title":"Tegoprazan- Versus PPI-based H. Pylori Eradication","status":"RECRUITING","sponsor":"Soonchunhyang University Hospital","startDate":"2024-12-01","conditions":"H.Pylori Infection","enrollment":200},{"nctId":"NCT03365609","phase":"NA","title":"A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children","status":"RECRUITING","sponsor":"Ying HUANG","startDate":"2017-09-20","conditions":"Helicobacter Infections","enrollment":1440},{"nctId":"NCT06823791","phase":"PHASE1, PHASE2","title":"Furazolidone Quadruple Regimen Eradicate H. Pylori Infection","status":"COMPLETED","sponsor":"Liaocheng People's Hospital","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection, Eradication","enrollment":493},{"nctId":"NCT06576882","phase":"PHASE3","title":"7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-30","conditions":"Helicobacter Pylori Infection, Gastritis, Vonoprazan","enrollment":326},{"nctId":"NCT05957432","phase":"PHASE2","title":"Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-08-15","conditions":"Helicobacter Pylori Infection","enrollment":90},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT06200779","phase":"PHASE4","title":"Tailored Vs. Empirical Helicobacter Pylori Infection Treatment","status":"NOT_YET_RECRUITING","sponsor":"Manuel Coelho da Rocha","startDate":"2025-09","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT06207786","phase":"NA","title":"Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2024-09-01","conditions":"Skin Cancer, Skin Cancer Face, Malignant Cutaneous Adnexal Neoplasm","enrollment":""},{"nctId":"NCT02387203","phase":"PHASE2","title":"Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mercy Medical Center","startDate":"2015-01","conditions":"Pseudomyxoma Peritonei, Appendiceal Neoplasms","enrollment":80},{"nctId":"NCT05475431","phase":"","title":"Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome","enrollment":1053},{"nctId":"NCT06591494","phase":"PHASE2, PHASE3","title":"The Efficacy of Quadruple Therapy Containing Sodium Bicarbonate as the Primary Treatment for Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09-15","conditions":"Helicobacter Pylori Infection","enrollment":855},{"nctId":"NCT06603688","phase":"PHASE4","title":"Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-11-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":548},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT06168214","phase":"PHASE4","title":"Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-09-04","conditions":"the Eradication Rates of Helicobacter Pylori","enrollment":1404},{"nctId":"NCT06546111","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate the Possible Efficacy and Safety of Diosmin and Hesperidin Combined Therapy in Patients With Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"Sadat City University","startDate":"2024-10-01","conditions":"Helicobacter Pylori Infection","enrollment":46},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06250634","phase":"NA","title":"Esomeprazole/Vonoprazan Combined With High-dose Amoxicillin Dual Therapy for Primary Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2024-02-10","conditions":"Helicobacter Pylori Infection","enrollment":806},{"nctId":"NCT04147065","phase":"PHASE4","title":"Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study)","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2021-07-14","conditions":"Helicobacter Pylori Infection","enrollment":1230},{"nctId":"NCT05169554","phase":"PHASE2","title":"Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy","status":"RECRUITING","sponsor":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID)","startDate":"2021-12-01","conditions":"Buruli Ulcer","enrollment":140},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT06382493","phase":"NA","title":"Tegoprazan-containing Sequential for H. Pylori","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-02-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT05664685","phase":"PHASE4","title":"Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-10-17","conditions":"Helicobacter Pylori Infection","enrollment":127},{"nctId":"NCT06318104","phase":"PHASE4","title":"Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole","status":"NOT_YET_RECRUITING","sponsor":"Hospital General de México Dr. Eduardo Liceaga","startDate":"2024-04-19","conditions":"Helicobacter Pylori Infection","enrollment":160},{"nctId":"NCT06315478","phase":"PHASE4","title":"Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-02-01","conditions":"H.Pylori Infection","enrollment":60},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT06216639","phase":"","title":"Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection","status":"UNKNOWN","sponsor":"National Institute of Public Health, Slovenia","startDate":"2024-02-01","conditions":"Helicobacter Pylori Infection","enrollment":2000},{"nctId":"NCT05297695","phase":"PHASE2, PHASE3","title":"Helicobacter Pylori Eradication Therapy for Epileptic Children","status":"COMPLETED","sponsor":"Sohag University","startDate":"2022-04-20","conditions":"Epilepsy, Generalized, Helicobacter Pylori Infection","enrollment":126},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT05453994","phase":"","title":"Bismuth for PCAB-based H. Pylori Eradication","status":"COMPLETED","sponsor":"Soonchunhyang University Hospital","startDate":"2020-03-01","conditions":"H. Pylori Infection","enrollment":150},{"nctId":"NCT02407119","phase":"PHASE3","title":"Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2003-06","conditions":"Helicobacter Pylori Infection, Early Gastric Cancer, Endoscopic Resection","enrollment":470},{"nctId":"NCT01678027","phase":"PHASE3","title":"Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2004-11","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Family Members","enrollment":1838},{"nctId":"NCT02547025","phase":"NA","title":"Personalized Treatment for Refractory H Pylori Infection","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2012-08-01","conditions":"Helicobacter Pylori Infection","enrollment":126},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT01133951","phase":"NA","title":"Helicobacter Pylori Eradication to Prevent Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jie-Jun Wang","startDate":"2010-06","conditions":"Helicobacter Infections, Stomach Neoplasms","enrollment":3000},{"nctId":"NCT01273441","phase":"PHASE4","title":"Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2010-12","conditions":"Helicobacter Pylori","enrollment":338},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT04198363","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-04-30","conditions":"Helicobacter Pylori","enrollment":510},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT06004401","phase":"NA","title":"The Observation on the Efficacy of Dual Therapy Based on Vonoprazan in Eradicating Helicobacter Pylori","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2023-08-20","conditions":"The Eradication Rate of Helicobacter Pylori","enrollment":400},{"nctId":"NCT05371249","phase":"PHASE4","title":"Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy","status":"UNKNOWN","sponsor":"Fu Jen Catholic University Hospital","startDate":"2021-12-01","conditions":"Helicobacter Pylori","enrollment":628},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05933031","phase":"PHASE2","title":"Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-02-27","conditions":"Helicobacter Pylori Infection","enrollment":381},{"nctId":"NCT05915871","phase":"PHASE1","title":"Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2023-03-23","conditions":"Healthy","enrollment":22},{"nctId":"NCT05870397","phase":"NA","title":"Optimal Recheck Time for Helicobacter Pylori Eradication: A Prospective Randomized Trial","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-04-21","conditions":"Helicobacter Pylori Eradication","enrollment":900},{"nctId":"NCT05861687","phase":"PHASE2, PHASE3","title":"Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children","status":"COMPLETED","sponsor":"Finni Kollins","startDate":"2021-08-01","conditions":"Helicobacter Pylori Infection","enrollment":51},{"nctId":"NCT05718609","phase":"PHASE4","title":"Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-01","conditions":"Helicobacter Pylori Infection","enrollment":855},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT02359331","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection","status":"TERMINATED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":370},{"nctId":"NCT05786807","phase":"PHASE4","title":"Effect of H. Pylori Eradication on Alleviating Symptoms in Functional Dyspepsia Patients","status":"UNKNOWN","sponsor":"Wonkwang University Hospital","startDate":"2022-03-07","conditions":"Helicobacter Pylori-positive With Functional Dyspepsia","enrollment":315},{"nctId":"NCT05419674","phase":"PHASE4","title":"Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection","enrollment":393},{"nctId":"NCT05662514","phase":"NA","title":"Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-02-15","conditions":"Helicobacter Pylori Infection, Gut Microbiota","enrollment":100},{"nctId":"NCT05342532","phase":"PHASE4","title":"High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-06-12","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20230816","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220304","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20240611","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20230718","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220414","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20220304","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20161007","type":"ORIG","sponsor":"RISING","applicationNumber":"ANDA206006"},{"date":"20240612","type":"SUPPL","sponsor":"RISING","applicationNumber":"ANDA206006"}],"publicationCount":480,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Supercillin, Klaricid"],"phase":"marketed","status":"active","brandName":"Amoxicillin, Clarithromycin","genericName":"Amoxicillin, Clarithromycin","companyName":"Mackay Memorial Hospital","companyId":"mackay-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin and clarithromycin are antibiotics that work together to inhibit bacterial protein synthesis and cell wall formation, commonly used in combination therapy for H. pylori eradication. Used for Helicobacter pylori infection (as part of combination therapy), Respiratory tract infections, Gastrointestinal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}